Homepage Top Section1

As part of the partnership, RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s, after securing regulatory approval in India. Developed by the Gamaleya National

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from

The fine has been imposed on the companies for pushing the sales of Lucentis to treat age-related macular degeneration (AMD) over Avastin, which is available at low cost

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

AstraZeneca has initiated a phase 1 trial of a monoclonal antibody combination called AZD7442, which is being developed for the prevention and treatment of Covid-19. Dubbed as NCT04507256,

The manufacturing of the AZD1222 vaccine candidate will be taken up at Catalent’s commercial gene therapy manufacturing plant in Harmans, Maryland. Catalent said that it will prepare the

TYVYT, which was co-developed by Innovent and Lilly in China, is an anti-PD-1 monoclonal antibody immuno-oncology medicine. The duo began selling the drug in the country since 2019

Licensed from the Oxford University, the AZD1222 vaccine candidate had delivered strong immune responses against the Covid-19 causing SARS-CoV-2 virus in all participants in a phase I/II trial

Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential